Updates are available Correction dated 2024-04-04
Click to view Correction: https://doi.org/10.1007/s00404-024-07502-5
-
Authors
Römer, Thomas
Frenz, Ann-Kathrin
Dietrich-Ott, Susanne
Fiedler, Anja
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03182140 at ClinicalTrials.govDocuments that mention this clinical trial
The use of LNG-IUS-19.5 mg in daily gynecological routine practice in Germany: data from the Kyleena™ Satisfaction Study (KYSS)
https://doi.org/10.1007/s00404-024-07421-5
-
Funding
Funding for this research was provided by:
Bayer
- License Information
-
More Information
Article History
Received: 16 January 2024
Accepted: 5 February 2024
First Online: 29 February 2024
Change Date: 4 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00404-024-07502-5
Declarations
:
: Thomas Römer has received honoraria for lectures and advisory boards from Bayer, Exeltis, Gedeon Richter, Hexal, and Theramex. Ann-Kathrin Frenz is an employee of Bayer AG, Berlin, Germany. Susanne Dietrich-Ott is an employee of Jenapharm GmbH & Co. KG, Jena, Germany. Anja Fiedler declares no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval from Ethik-Kommission der Aerztekammer Nordrhein and Ethik-Kommission bei der Landesärztekammer Hessen was obtained prior to study start in June 2017 for all participating German centers.
: Written informed consent was obtained from all participants.
: Written informed consent was obtained from all participants.
